IL18 and neoplasm: Treatment of tumor-bearing mice with a combination of anti-CTLA-4 mAb and anti-PD-L1 mAb together with IL-18 led to the accumulation of activated NK cells, and depletion of either NK cells or CD8+ T cells abrogated the therapeutic effects of ICB plus IL-18 (10), indicating essential roles of these lymphocyte populations.